As WuXi AppTec’s man­u­fac­tur­ing rev­enue re­cov­ers, it said it is sell­ing its clin­i­cal re­search ser­vices busi­ness in Chi­na to a Sin­ga­pore-head­quar­tered pri­vate eq­ui­ty firm.

WuXi AppTec an­nounced on Mon­day that its con­tract re­search or­ga­ni­za­tion (CRO) WuXi Clin­i­cal and its sep­a­rate site man­age­ment unit WuXi Med­Key are set to go to Hill­house In­vest­ment Man­age­ment. No fi­nan­cial de­tails were giv­en. Hill­house has of­fices in Sin­ga­pore, Hong Kong, Bei­jing and Shang­hai, as well as in New York and Lon­don.

The ser­vice provider’s lat­est move comes as its man­u­fac­tur­ing rev­enue has start­ed to tick up­wards, af­ter the Biose­cure Act caused its busi­ness to slide in 2024. Al­though much like the wider CRO in­dus­try, its clin­i­cal ser­vices faced head­winds this year.

WuXi AppTec is clos­ing down its con­tract re­search or­ga­ni­za­tion in Austin, TX by the end of the year, a com­pa­ny spokesper­son told End­points News.

The move is part of a goal to “sharp­en” its fo­cus on its CRD­MO busi­ness, the spokesper­son said.

The de­ci­sion to shut down its WuXi Clin­i­cal busi­ness in Texas comes af­ter it said on Mon­day it would sell its Chi­na-based clin­i­cal ser­vices to pri­vate eq­ui­ty firm Hill­house In­vest­ment Man­age­ment.

WuXi AppTec’s clin­i­cal re­search ser­vices dropped in over­all rev­enue by 6.4% in the first three quar­ters of the year, reach­ing 1.21 bil­lion yuan ($170 mil­lion). The com­pa­ny does not typ­i­cal­ly split its US and Chi­na sales for this part of the busi­ness.

The spokesper­son did not pro­vide fur­ther de­tails on how many peo­ple could be laid off.

The FDA sent an un­usu­al in­spec­tion re­port late last month to the In­di­an gener­ic drug­mak­er Het­ero Labs af­ter un­cov­er­ing an unau­tho­rized ware­house hold­ing drugs and ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs) that was al­so in­fest­ed with lizards, birds and cats.

Ac­cord­ing to the Form 483, re­leased Fri­day, FDA in­spec­tors ar­rived at Het­ero's Visakha­p­at­nam, In­dia-based ware­house in late Sep­tem­ber and were de­nied en­try for ap­prox­i­mate­ly two hours.

The ware­house holds key start­ing ma­te­ri­als, in­clud­ing "in­ter­me­di­ates and fin­ished APIs for US FDA reg­is­tered man­u­fac­tur­ing fa­cil­i­ties that rou­tine­ly dis­trib­ute to the US mar­ket and to fa­cil­i­ties that man­u­fac­ture fin­ished drug prod­ucts for the US."

Staff at the site "ran out of plain sight" when the FDA in­spec­tors an­nounced their in­tent to in­spect the fa­cil­i­ty. When they fi­nal­ly did get in­to the ware­house, they un­cov­ered nu­mer­ous is­sues, even as the com­pa­ny em­ploy­ees claimed the ware­house is on­ly for dis­tri­b­u­tion to the do­mes­tic In­di­an drug mar­ket.

Eli Lil­ly is mak­ing an­oth­er move to help boost pro­duc­tion for its oral GLP-1 fran­chise, with a new $1.2 bil­lion in­vest­ment to ex­pand its fac­to­ry in Puer­to Ri­co.

Con­struc­tion to add on­to the fa­cil­i­ty ded­i­cat­ed to make or­for­glipron will be­gin in 2026, and it is ex­pect­ed to be op­er­a­tional by the end of 2028. Lil­ly ex­pects to sub­mit the drug to the FDA for obe­si­ty by the end of the year and then for type 2 di­a­betes in 2026. The fa­cil­i­ty will cre­ate around 100 new jobs.

But even be­fore the Puer­to Ri­co site is com­plete, the drug­mak­er has al­ready made “sig­nif­i­cant quan­ti­ties of the ma­te­r­i­al” ahead of the pil­l's com­mer­cial launch, Edgar­do Her­nan­dez, EVP and pres­i­dent of man­u­fac­tur­ing op­er­a­tions, told End­points News.

Ther­mo Fish­er an­nounced Wednes­day that it will pay $8.9 bil­lion in cash to ac­quire the da­ta so­lu­tions com­pa­ny Clario.

In ad­di­tion to the up­front pay­ment, Ther­mo has agreed to shell out $125 mil­lion in Jan­u­ary 2027, and up to $400 mil­lion in ad­di­tion­al earnouts based on busi­ness per­for­mance over the next two years, mak­ing the to­tal deal worth up to $9.4 bil­lion. Ther­mo will buy Clario from a share­hold­er group led by As­torg and Nordic Cap­i­tal, No­vo Hold­ings and Cin­ven.

Ther­mo CEO Marc Casper said in a news re­lease that Clario’s tech­nol­o­gy, which in­cludes a dig­i­tal end­point plat­form and AI tools, will en­able “faster, more in­formed drug de­vel­op­ment" and "fur­ther ac­cel­er­ate the dig­i­tal trans­for­ma­tion of clin­i­cal re­search.” Clario has 4,000 em­ploy­ees and is ex­pect­ed to gen­er­ate $1.25 bil­lion in 2025 rev­enue.

Eu­ro­pean health­care spe­cial­ist GHO Cap­i­tal has nabbed €2.5 bil­lion (~$2.9 bil­lion) for its fourth fund.

The raise comes in at al­most $1 bil­lion more than GHO’s third fund in 2021. GHO’s cof­fers have steadi­ly grown over the years. That third fund was about dou­ble the size of the sec­ond, dis­closed in 2019.

The Lon­don-based firm, short for Glob­al Health­care Op­por­tu­ni­ties, col­lect­ed its newest fund from ex­ist­ing in­vestors plus 30 new in­sti­tu­tion­al back­ers spread across Eu­rope, North Amer­i­ca, Asia Pa­cif­ic and the Mid­dle East.

With about €9 bil­lion in as­sets un­der man­age­ment, GHO said it is the largest health­care spe­cial­ist PE firm based in Eu­rope.

It in­vests across the gamut of health­care: bio­phar­ma, medtech, life sci­ences tools, di­ag­nos­tics, health tech and ad­vi­so­ry and da­ta ser­vices.